Heart Rate Variability (HRV) in Pituitary Adenoma

A Study to Observe the Change of the Biological Signal (Heart Rate) During the Combined Pituitary Stimulation Test

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03164148

Enrollment

Registered

2017-05-23

Start date

2017-05-17

Completion date

2018-05-16

Last updated

2017-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Adenoma

Brief summary

Several studies have been reported that heart rate is known to be associated with prognosis in chronic diseases and acute diseases. For example, a decrease in heart rate following myocardial infarction may lead to a higher mortality rate. It is also known to predict heart failure, diabetic neuropathy, and even depression. The combined pituitary function test artificially induces hypoglycemia to observe the secretion of pituitary hormone. The degree of change in heart rate during hypoglycemia can predict the adequacy of the test, and heart rate can be changed according to the characteristic of the tumor. Also, the prognosis can be predicted based on this. In our study, we used a licensed device approved by KFDA (Korea Food and Drug Administration) to measure heart rate variability in patients with pituitary adenoma.

Interventions

DEVICET-REX TRI00A

Case management consists of confirmation of hospital visit date, checking the adverse effect

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Over 19 year old * Those with Normal blood pressure range: 90mmHg \<systolic \<140mmHg, 60mmHg \<diastolic \<100mmHg * Voluntary participants who visited Seoul St. Mary's Hospital

Exclusion criteria

* Those who have been diagnosed with sleep disorders, diabetes, arrhythmia, psychiatric disorder, physical or mental breakdown, drug addicts * Diabetes, hypertension, cardiovascular disease diagnosed by taking a drug related to the disease * Pregnant or lactating women * Those who drank within 12 hours before participating in the trial * Those who are deemed inappropriate by clinical trial researchers

Design outcomes

Primary

Measure	Time frame
Changes in Heart rate variability according to the types of pituitary adenoma	5 month of initial recruit

Countries

South Korea

Contacts

Primary ContactJeonghoon Ha, M.D

hajhoon@catholic.ac.kr82-2-2258-6372

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026